{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:49:59Z","timestamp":1761709799552,"version":"build-2065373602"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.mehy.2020.110473","type":"journal-article","created":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T12:23:49Z","timestamp":1608812629000},"page":"110473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced \u201ccytokines storm\u201d"],"prefix":"10.1016","volume":"146","author":[{"given":"Cesidio","family":"Giuliani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ines","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgio","family":"Napolitano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2020.110473_b0005","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1677\/JOE-09-0172","article-title":"Regulation of major histocompatibility complex gene expression in thyroid epithelial cells by methimazole and phenylmethimazole","volume":"204","author":"Giuliani","year":"2010","journal-title":"J Endocrinol"},{"key":"10.1016\/j.mehy.2020.110473_b0010","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.4049\/jimmunol.173.3.2041","article-title":"Phenyl methimazole inhibits TNF-\u03b1-induced VCAM-1 expression in an IFN regulatory factor-1-dependent manner and reduces monocytic cell adhesion to endothelial cells","volume":"173","author":"Dagia","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.mehy.2020.110473_b0015","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1210\/me.2004-0100","article-title":"Thyrocytes express a functional toll-like receptor 3: overexpression can be induced by viral infection and reversed by phenylmethimazole and is associated with Hashimoto\u2019s autoimmune thyroiditis","volume":"19","author":"Harii","year":"2005","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.mehy.2020.110473_b0020","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1097\/CCM.0b013e318236ef8b","article-title":"Phenylmehimazole inhibits production of proinflammatory mediators and is protective in an experimental model of endotoxic shock","volume":"40","author":"Benavides-Peralta","year":"2012","journal-title":"Crit Care Med"},{"key":"10.1016\/j.mehy.2020.110473_b0025","unstructured":"Kohn LD, Harii N, Benavides-Peralta U, et al. Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune\/inflammatory diseases associated with toll-like receptor overexpression. United States patent 2016 U.S. 9,326,972."},{"key":"10.1016\/j.mehy.2020.110473_b0030","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.mehy.2020.110473_b0035","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1172\/JCI137647","article-title":"SARS-CoV-2: a storm is raging","volume":"130","author":"Pedersen","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.mehy.2020.110473_b0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.mehy.2020.110473_b0045","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"10.1016\/j.mehy.2020.110473_b0050","doi-asserted-by":"crossref","first-page":"e370","DOI":"10.1016\/S2665-9913(20)30165-X","article-title":"Coronavirus is the trigger, but the immune response is deadly","volume":"2","author":"Cron","year":"2020","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"10.1016\/j.mehy.2020.110473_b0055","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S2665-9913(20)30120-X","article-title":"The immunology of COVID-19: is immune modulation an option for treatment?","volume":"2","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.mehy.2020.110473_b0060","first-page":"1","article-title":"Immune therapy, or antiviral therapy, or both for COVID-19: a systematic review","author":"Cantini","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.mehy.2020.110473_b0065","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1146\/annurev-pathol-020712-164041","article-title":"Pathogenesis of the viral hemorrhagic fevers","volume":"8","author":"Paessler","year":"2013","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"10.1016\/j.mehy.2020.110473_b0070","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3389\/fphar.2019.01691","article-title":"Opinion: an existing drug to assess in vivo for potential adjunctive therapy of Ebola virus disease and post-Ebola syndrome","volume":"10","author":"Hendricks","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.mehy.2020.110473_b0075","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.toxicon.2017.10.016","article-title":"Exotoxins and endotoxins: Inducers of inflammatory cytokines","volume":"149","author":"Cavaillon","year":"2018","journal-title":"Toxicon"},{"key":"10.1016\/j.mehy.2020.110473_b0080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13613-019-0543-6","article-title":"Preclinical septic shock research: why we need an animal ICU","volume":"9","author":"Guillon","year":"2019","journal-title":"Ann. Intensive Care"},{"key":"10.1016\/j.mehy.2020.110473_b0085","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/SHK.0000000000001242","article-title":"Part II: minimum quality threshold in preclinical sepsis studies (MQTiPSS) for types of infections and organ dysfunction endpoints","volume":"51","author":"Libert","year":"2019","journal-title":"SHOCK"},{"key":"10.1016\/j.mehy.2020.110473_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/SHK.0000000000001243","article-title":"Part I: minimum quality threshold in preclinical sepsis studies (MQTiPSS) for study design and humane modeling endpoints","volume":"51","author":"Zingarelli","year":"2019","journal-title":"SHOCK"},{"key":"10.1016\/j.mehy.2020.110473_b0095","doi-asserted-by":"crossref","first-page":"102801","DOI":"10.1016\/j.ebiom.2020.102801","article-title":"COVID-19 as a STING disorder with delayed over-secretion of interferon-beta","volume":"56","author":"Berthelot","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720333648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987720333648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T19:21:59Z","timestamp":1759692119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987720333648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":19,"alternative-id":["S0306987720333648"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110473","relation":{},"ISSN":["0306-9877"],"issn-type":[{"type":"print","value":"0306-9877"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced \u201ccytokines storm\u201d","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2020.110473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110473"}}